Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The myelodysplastic syndromes.

E G Sims

    Journal of the National Medical Association
    |July 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Myelodysplastic syndromes (MDS) are blood disorders with abnormal cell development. Diagnosis relies on clinical and lab features, with varied patient outcomes and treatment approaches.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hypothyroidism causing macrocytic anemia unresponsive to B12 and folate.

    Journal of the National Medical Associationยท1983
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Cell Biology

    Background:

    • Myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders.
    • Characterized by ineffective hematopoiesis, leading to cytopenias and a high risk of transformation to acute myeloid leukemia (AML).
    • Current diagnostic criteria and classification systems aim to standardize identification and prognostication.

    Purpose of the Study:

    • To review the heterogeneous nature of myelodysplastic syndromes.
    • To discuss diagnostic challenges and current classification systems.
    • To outline the variable natural history and therapeutic options for MDS patients.

    Main Methods:

    • Literature review of myelodysplastic syndromes.
    • Analysis of diagnostic criteria and classification systems.

    Related Experiment Videos

  • Summary of prognostic factors and treatment modalities.

    • Main Results:

    • MDS encompasses a spectrum of myeloid neoplasms with distinct morphologic features.
    • The French-American-British (FAB) classification identifies five subgroups but only two major prognostic groups.
    • Patient outcomes vary significantly, ranging from rapid AML progression to indolent disease with prolonged survival.

    Conclusions:

    • Effective management of MDS requires a comprehensive understanding of its heterogeneity.
    • Treatment strategies are tailored to individual prognostic factors and patient status.
    • Supportive care remains crucial for managing complications associated with ineffective hematopoiesis.